AccScience Publishing / GTM / Online First / DOI: 10.36922/gtm.4957
Submit to GTM
Cite this article
3
Download
20
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Prediction of in-stent restenosis based on systematic and retrospective analyses

Alina M. Enikeeva1,2 ,  Liutsiia Yu. Gazizova2 ,  Igor V. Buzaev1 ,  Irina E. Nikolaeva1,2 ,  Irina A. Lakman3 ,  Haibo Jia4 ,  Tagir Aminov1,2 ,  Elena A. Badykova1 ,  Naufal Sh. Zagidullin1*
Show Less
1 Department of Internal Diseases, Bashkir State Medical University, Ufa, Republic of Bashkortostan, Russia
2 Department of Cardiology, Republic Cardiological Centre, Ufa, Republic of Bashkortostan, Russia
3 Laboratory for the Study of Socio-Economic Problems of the Regions, Ufa University of Science and Technology, Ufa, Republic of Bashkortostan, Russia
4 National Key Laboratory of Frigid Zone Cardiovascular Diseases, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Global Translational Medicine, 4957 https://doi.org/10.36922/gtm.4957
Submitted: 26 September 2024 | Accepted: 22 November 2024 | Published: 26 December 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Coronary restenosis is a pressing challenge in cardiovascular diseases with an annual incidence of 3 – 4%. The aim of the study was to assess the influence of known risk factors in predicting coronary restenosis in a systematic analysis and an original retrospective survey. In the first stage, we performed a systematic review of restenosis risk factors using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. In the second stage, we searched for the restenosis risk factors in 15,000 patients who had undergone coronary angiography, considering risk factors identified during the first stage. From the second stage, we identified 516 patients with restenosis versus 282 patients without restenosis. Coronary risk factors included male sex (hazard ratio [HR] = 2.194; confidence interval [CI]: 1.5 – 3.22) and history of myocardial infarction (HR = 1.098; CI: 1.05 – 1.15). Moderate-diameter stenosis (2.75 – 3.5 mm) exhibited a protective effect on restenosis (HR = 0.713; CI: 0.58 – 0.87), whereas small-diameter stenosis did not. Drug-eluting stents reduced the risk of restenosis (HR = 0.554; CI: 0.41 – 0.75). The risk factors for coronary restenosis included male sex, history of myocardial infarction, small-diameter stent, and the use of bare-metal stents.

Keywords
Coronary heart disease
Coronary restenosis
Risk factors
Drug-eluting stent
Bare metal stent
Funding
None.
Conflict of interest
Naufal Sh. Zagidullin is the Editorial Board Member of this journal and Guest Editor of this special issue but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7

 

  1. Townsend N, Kazakiewicz D, Wright FL, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19(2):133-143. doi: 10.1038/s41569-021-00607-3

 

  1. Russian Statistical Yearbook 2021. Russia: Federal State Statistics Service; 2021. p. 692.

 

  1. Karpin AD, Starvinsky VV, Shakhzadova AO, Lisichnikova IV. Malignant Neoplasms in Russia in 2021 (Morbidity and Mortality). Russia: Federal State Statistics Service; 2022. p. 233.

 

  1. The Demographic Yearbook of Russia 2021. Russia: Federal State Statistics Service; 2021. p. 256.

 

  1. Alekyan BG, Grigoryan AM, Staferov AV, Karapetyan NG. X-ray endovascular diagnostics and treatment of heart and vascular diseases in the Russian Federation. Endovasc Surg J. 2021;8:233.

 

  1. Kalinina AM, Ipatov PV, Kushunina DV, et al. Results of circulatory disease detection during prophylactic medical examination of the adult population: The first two years’ experience. Terapevticheskii Arkhiv. 2016;88(1):46-52.

 

  1. Stone G, Maehara A, Lansky A, et al. A prospective natural - history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226-235. doi: 10.1056/NEJMoa1002358

 

  1. Ullrich H, Olschewski M, Münzel T, Gori T. Coronary in-stent restenosis: Predictors and treatment. Dtsch Arztebl Int. 2021;118(38):637-644. doi: 10.3238/arztebl.m2021.0254

 

  1. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659-2673. doi: 10.1016/j.jacc.2014.02.545

 

  1. Hamon M, Bauters C, McFadden EP, et al. Restenosis after coronary angioplasty. Eur Heart J. 1995;16(Suppl I):33-48. doi: 10.1093/eurheartj/16.suppl_i.33

 

  1. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011;9:53-62. doi: 10.1038/nrcardio.2011.132

 

  1. Buccheri D, Cimino G. Drug-eluting stent restenosis treatment: An “old” stent, a “new” balloon or a “newer” scaffold? J Thorac Dis. 2016;8(12):3478-3483. doi: 10.21037/jtd.2016.12.21

 

  1. Gori T. Restenosis after coronary stent implantation: Cellular mechanisms and potential of endothelial progenitor cells (a short guide for the interventional cardiologist). Cells. 2022;11(13):2094. doi: 10.3390/cells11132094

 

  1. Neubauer K, Zieger B. Endothelial cells and coagulation. Cell Tissue Res. 2022;387:391-398. doi: 10.1007/s00441-021-03471-2

 

  1. Timmis A, Townsend N, Gale C, et al. European society of cardiology: Cardiovascular disease statistics 2017. Eur Heart J. 2018;39:508-579. doi: 10.1093/eurheartj/ehx628

 

  1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. doi: 10.1056/NEJMoa035071

 

  1. Shumakov DV, Shekhyan GG, Zybin DI, Yalymov AA, Vedenikin TY, Popov MA. In-stent restenosis: Symptoms, hemodynamic signs, pathogenesis and treatment. Russ Cardiol Bull. 2021;16(1):20-27. doi: 10.17116/cardiobulletin20211601120

 

  1. Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: A report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol. 2009;53(18): 1660-1667. doi: 10.1016/j.jacc.2009.01.054

 

  1. MacRury SM, Lowe GD. Blood rheology in diabetes mellitus. Diabet Med. 1990;7(4):285-291. doi: 10.1111/j.1464-5491.1990.tb01391.x37

 

  1. Ostermann H, van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis. 1986;16(6):386-416. doi: 10.1159/000215317

 

  1. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/dele-tion polymorphism of angiotensin I-converting enzyme: A major risk factor and a marker of risk for coronary stent restenosis. Circulation. 1998;97(2):147-154. doi: 10.1161/01.cir.97.2.14741

 

  1. Vogiatzi K, Apostolakis S, Voudris V, Thomopoulou S, Kochiadakis GE, Spandidos DA. Interleukin 8 gene polymorphisms and susceptibility to rest-enosis after percutaneous coronary intervention. J Thromb Thrombolysis. 2010;29(1):134-140. doi: 10.1007/s11239-009-0338-y42

 

  1. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging im-portance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updates. 2005;8(5):311-321. doi: 10.1016/j.drup.2005.09.001

 

  1. Iijima R, Byrne RA, Ndrepepa G, et al. Pre-procedural C-reactive protein levels and clinical out-comes after percutaneous coronary interventions with and without ABCIX-IMAB: Pooled analysis of four ISAR trials. Heart. 2009;95(2):107-112. doi: 10.1136/hrt.2008.15363547

 

  1. Dibra A, Mehilli J, Braun S, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with rest-enosis in patients treated with coronary stenting. Am Heart J. 2005;150(2):344-350. doi: 10.1016/j.ahj.2004.09.030

 

  1. Moreno PR, Bernardi VH, López-Cuéllar J, et al. Macrophage infiltration predicts rest-enosis after coronary intervention in patients with unstable angina. Circulation. 1996;94(12):3098-3102. doi: 10.1161/01.cir.94.12.3098

 

  1. Katsaros KM, Wiesbauer F, Speidl WS, et al. High soluble Fas and soluble Fas ligand serum levels before stent implantation are protective against restenosis. Thromb Haemostasis. 2011;105(5):883-891. doi: 10.1160/TH10-09-0566

 

  1. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109(9):1085-1088. doi: 10.1161/01.CIR.0000121327.67756.19

 

  1. Coughlan JJ, Aytekin A, Lahu S, et al. Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary interventions for recurrent drug-eluting stent restenosis. EuroIntervention. 2023;18:e1328-e1338. doi: 10.4244/EIJ-D-22-00860

 

  1. Takebayashi H, Mintz GS, Carlier SG, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2004;110(22):3430-3434. doi: 10.1161/01.CIR.0000148371.53174.05

 

  1. Guo X, Shen R, Yan S, Su Y, Ma L. Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2023;22(1):43. doi: 10.1186/s12933-023-01779-7

 

  1. Cabrera-Rego JO, Escobar-Torres RA, Parra-Jiménez JD, Valiente-Mustelier J. Epicardial fat thickness correlates with coronary in-stent restenosis in patients with acute myocardial infarction. Clin Investig Arterioscler. 2019;31(2):49-55. doi: 10.1016/j.arteri.2018.11.002

 

  1. Zhang W, Zhang M, Tian J, Zhang M, Zhou Y, Song X. Drug-coated balloon-only strategy for de novo coronary artery disease: A meta-analysis of randomized clinical trials. Cardiovasc Ther. 2023;8:3121601. doi: 10.1155/2023/3121601

 

  1. Kokkinidis DG, Waldo SW, Armstrong EJ. Treatment of coronary artery in-stent restenosis. Expert Rev Cardiovasc Ther. 2017;15(3):191-202. doi: 10.1080/14779072.2017.1284588

 

  1. Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. Eurointervention. 2020;15(17):1527-1533. doi: 10.4244/EIJ-D-19-00723

 

  1. Zhang J, Zhang Q, Zhao K, Bian YJ, Liu Y, Xue YT. Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study. Medicine (Baltimore). 2022;101(47):e31707. doi: 10.1097/MD.0000000000031707

 

  1. Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: A comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J. 2020;41:3715-3728. doi: 10.1093/eurheartj/ehz594

 

  1. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/ EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019;14:1435-1534. doi: 10.4244/EIJY19M01_01
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: 3060-8600, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept